Sirtuin deacetylases: A new target for melanoma management

Cell Cycle

Volumn 13, Issue 18, 2014, Pages 2821-2826

  Wilking, Melissa J ^a   Singh, Chandra K ^a   Nihal, Minakshi ^a   Ndiaye, Mary A ^a   Ahmad, Nihal ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cellular localization; Melanoma; PI3K; SIRT1; SIRT1 inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; EX 527; HISTONE DEACETYLASE INHIBITOR; PROTEIN P53; SIRTINOL; SIRTUIN; SIRTUIN 1; SMALL INTERFERING RNA; TENOVIN 1; UNCLASSIFIED DRUG; 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE; BENZAMIDE DERIVATIVE; CARBAZOLE DERIVATIVE; HISTONE DEACETYLASE 3; NAPHTHOL DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER THERAPY; CELL GROWTH; CELL VIABILITY; CELLULAR DISTRIBUTION; DRUG ACTIVITY; DRUG EFFICACY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; MELANOMA; MELANOMA CELL LINE; PROTEIN LOCALIZATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL CLONE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BENZAMIDES; CARBAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLONE CELLS; GROUP III HISTONE DEACETYLASES; HUMANS; MELANOMA; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NAPHTHOLS; SIGNAL TRANSDUCTION;

EID: 84908199076     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.949085     Document Type: Article

References (20)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, CA Cancer J Clin 2014; 64:9-29; PMID:24399786
2. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncol (Williston Park) 2009; 23:488-96
3. Chakraborty R, Wieland CN, Comfere NI. Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med 2013; 6:49-56; PMID:23843700
4. Klinac D, Gray ES, MillwardM, Ziman M. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013; 3:54; PMID:23515890; http://dx.doi.org/10.3389/fonc.2013.00054
5. Wilking MJ, Singh C, Nihal M, Zhong W, Ahmad N. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts antiproliferative response via p53 activation. Arch Biochem Biophys 2014; http://dx.doi.org/10.1016/j.abb.2014.04.001; PMID:24751483
6. Stunkel W, Campbell RM. Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen 2011; 16:1153-69; PMID:22086720; http://dx.doi.org/10.1177/1087057111422103
7. Kunimoto R, Jimbow K, Tanimura A, Sato M, Horimoto K, Hayashi T, Hisahara S, Sugino T, Hirobe T, Yamashita T, et al. SIRT1 regulates lamellipodium extension and migration of melanoma cells. J Invest Dermatol 2014; 134:1693-700; PMID:24480879; http://dx.doi.org/10.1038/jid.2014.50
8. Ohanna M, Bonet C, Bille K, Allegra M, Davidson I, Bahadoran P, Lacour J-P, Ballotti R, Bertolotto C. SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells. Oncotarget 2014; 5:2085-95; PMID:24742694
9. Singh CK, George J, Nihal M, Sabat G, Kumar R, Ahmad N. Novel downstream molecular targets of SIRT1 inmelanoma: a quantitative proteomics approach. Oncotarget 2014; 5:1987-99; PMID:24743044
10. Allison SJ, Milner J. SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle 2007; 6:2669-77; PMID:17957139; http://dx.doi.org/10.4161/cc.6.21.4866
11. Inoue T, Hiratsuka M, Osaki M, Oshimura M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 2007; 6:1011-8; PMID:17457050; http://dx.doi.org/10.4161/cc.6.9.4219
12. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13:454-63; PMID:18455128; http://dx.doi.org/10.1016/j.ccr.2008.03.004
13. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001; 276:38837-43; PMID:11483616; http://dx.doi.org/10.1074/jbc.M106779200
14. Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, Barker J, Yau WT, Amouzegh P, Flegg A, Hamelin E, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005; 48:8045-54; PMID:16335928; http://dx.doi.org/10.1021/jm050522v
15. Bouras T, Fu M, Sauve AA, Wang F, Quong AA, Perkins ND, Hay RT, Gu W, Pestell RG. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem 2005; 280:10264-76; PMID:15632193; http://dx.doi.org/10.1074/jbc. M408748200
16. Han Y, Jin YH, Kim YJ, Kang BY, Choi HJ, Kim DW, Yeo CY, Lee KY. Acetylation of Sirt2 by p300 attenuates its deacetylase activity. Biochem Biophys Res Commun 2008; 375:576-80; PMID:18722353; http://dx.doi.org/10.1016/j.bbrc.2008.08.042
17. Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, Dai Y. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci 2010; 6:599-612; PMID:20941378; http://dx.doi.org/10.7150/ijbs.6.599
18. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic Shuttling of the NADC-dependent Histone Deacetylase SIRT1. J Biol Chem 2007; 282:6823-32; PMID:17197703; http://dx.doi.org/10.1074/jbc.M609554200
19. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol 2014; 4:64; PMID:24782981; http://dx.doi.org/10.3389/fonc.2014.00064
20. Khaled M, Larribere L, Bille K, Ortonne J-P, Ballotti R, Bertolotto C. Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-Kinase pathway. 2003; 121:831-6; PMID:14632202